Truncated MOG MBP PLP Protein Composition for Demyelinating Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for demyelinating diseases like multiple sclerosis are inadequate, as they fail to effectively address the autoimmune and inflammatory aspects of the condition, leading to significant disability and reduced lifespan for patients.
Innovation Solution
A protein composition comprising truncated myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), and proteolipid protein (PLP) amino acid sequences, conjugated or fused together, is administered to induce immunologic tolerance and reduce autoimmune responses, thereby ameliorating the autoimmune and inflammatory aspects of demyelinating diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for demyelinating diseases are used, then patient survival is maintained, but autoimmune responses and inflammatory damage to the myelin sheath are not effectively controlled
Solution Approach 1:
The invention uses the harmful autoimmune response mechanism itself as the treatment mechanism. By administering a composition containing myelin antigens (MOG, MBP, PLP), the patent converts the harmful autoimmune attack into a beneficial immunomodulatory effect, where the immune system is redirected to produce regulatory T cells that suppress the pathological autoimmune response against myelin
Solution Approach 2:
The myelin antigen composition acts as an intermediary substance that mediates between the immune system and the myelin sheath. The composition includes specific myelin proteins (MOG amino acid sequence, MBP amino acid sequence, PLP amino acid sequence) that serve as intermediaries to induce immunologic tolerance and regulate the autoimmune response
2Object-affected harmful factors
If conventional immunosuppressive therapies are applied, then inflammation is reduced, but side effects and lack of targeted action increase
Solution Approach 1:
The invention applies local quality by targeting specifically the autoimmune response against myelin antigens rather than suppressing the entire immune system. The composition contains specific myelin proteins (MOG, MBP, PLP) that enable targeted modulation of the immune response, affecting only the pathological autoimmune pathways while preserving normal immune function
Solution Approach 2:
The invention changes the parameter of immune response specificity by using a composition with defined myelin antigen sequences. The amino acid sequences of MOG, MBP, and PLP are specifically selected and conjugated to create a treatment that modifies the immune response parameters to be more selective and less broadly suppressive than conventional immunosuppressants
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.